JP2024533119A5 - - Google Patents

Info

Publication number
JP2024533119A5
JP2024533119A5 JP2024513740A JP2024513740A JP2024533119A5 JP 2024533119 A5 JP2024533119 A5 JP 2024533119A5 JP 2024513740 A JP2024513740 A JP 2024513740A JP 2024513740 A JP2024513740 A JP 2024513740A JP 2024533119 A5 JP2024533119 A5 JP 2024533119A5
Authority
JP
Japan
Prior art keywords
antibody
seq
amino acid
acid sequence
cdr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024513740A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024533119A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2022/074455 external-priority patent/WO2023031403A1/en
Publication of JP2024533119A publication Critical patent/JP2024533119A/ja
Publication of JP2024533119A5 publication Critical patent/JP2024533119A5/ja
Pending legal-status Critical Current

Links

JP2024513740A 2021-09-02 2022-09-02 Amlの治療のための抗体 Pending JP2024533119A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163240342P 2021-09-02 2021-09-02
US63/240,342 2021-09-02
PCT/EP2022/074455 WO2023031403A1 (en) 2021-09-02 2022-09-02 Antibodies for the treatment of aml

Publications (2)

Publication Number Publication Date
JP2024533119A JP2024533119A (ja) 2024-09-12
JP2024533119A5 true JP2024533119A5 (enExample) 2025-09-04

Family

ID=83438540

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024513740A Pending JP2024533119A (ja) 2021-09-02 2022-09-02 Amlの治療のための抗体

Country Status (6)

Country Link
US (1) US20240352136A1 (enExample)
EP (1) EP4396230A1 (enExample)
JP (1) JP2024533119A (enExample)
CN (1) CN117916266A (enExample)
TW (1) TW202319400A (enExample)
WO (1) WO2023031403A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4719352A1 (en) 2023-05-31 2026-04-08 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
CN117192121A (zh) * 2023-08-30 2023-12-08 北京大学人民医院 用于mds和/或aml微小残留病检测的抗体组合物及其应用
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101545914B1 (ko) 2009-09-22 2015-08-20 프로바이오겐 아게 특수화된 글리칸 구조를 함유하는 분자의 생산 방법
GB201507827D0 (en) * 2015-05-07 2015-06-17 Adc Therapeutics Sarl Diagnostic test
PL3440109T3 (pl) 2016-04-07 2025-12-01 Cancer Research Technology Limited Przeciwciała przeciwko receptorowi gamma CD25 fc do zmniejszenia liczebności komórek swoistych dla nowotworu w skojarzeniu z antagonistami PD-1
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
WO2019008386A1 (en) 2017-07-06 2019-01-10 Tusk Therapeutics Ltd COMPOUNDS AND METHODS FOR DEPLOYING SPECIFIC CELLS FROM A TUMOR
KR102097449B1 (ko) 2017-07-17 2020-04-06 성균관대학교산학협력단 복수의 층간 인터락킹 구조를 포함하는 건식 접착 시스템
KR101930470B1 (ko) 2017-07-20 2019-03-14 (주)파트론 지문 센서 패키지
KR102570856B1 (ko) 2017-07-21 2023-08-25 상라오 징코 솔라 테크놀러지 디벨롭먼트 컴퍼니, 리미티드 페로브스카이트 태양전지 및 이를 포함하는 탬덤 태양전지
KR20190069030A (ko) 2017-12-11 2019-06-19 삼성전자주식회사 디스플레이 장치 및 그 제어 방법
CN112020516B (zh) 2018-03-13 2025-01-03 塔斯克疗法有限公司 用于肿瘤特异性细胞清除的抗-cd25
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療
JP2022536140A (ja) * 2019-06-10 2022-08-12 アーデーセー セラピューティクス ソシエテ アノニム 併用療法

Similar Documents

Publication Publication Date Title
KR102291971B1 (ko) 종양 성장 및 전이를 억제하기 위한 면역 조절 요법과 병용되는 세마포린-4d 억제성 분자의 용도
EP4313078A1 (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
AU2021203126A1 (en) Anti-GITR antibodies and methods of use thereof
EP4074732A1 (en) Fully human antibodies against ox40, method for preparing the same, and use thereof
RU2625222C2 (ru) Комбинированная терапия антителом к cd19 и азотистым ипритом
AU2016311136B2 (en) Combinations and uses thereof
TW201902514A (zh) Pd-1抗體與vegf配體或vegf受體抑制劑聯合在製備治療腫瘤的藥物中的用途
US20230220106A1 (en) Antibodies targeting 5t4 and uses thereof
CN115210261B (zh) 抗半乳糖凝集素-9抗体及其用途
TW202330038A (zh) 用於治療癌症之b7-h4抗體-藥物結合物
Robak et al. Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia
EP3896089A1 (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
TW202216193A (zh) 包含抗CD19抗體及阻斷SIRPα-CD47先天免疫檢查點之多肽之抗腫瘤組合療法
KR20190137847A (ko) 항-cd25 항체-약물 접합체와의 병용 요법
KR20250039386A (ko) 항-fcrh5/항-cd3 이중특이적 항체를 이용한 치료를 위한 투약법
KR20230048112A (ko) Cd40 효능성 항체 및 이의 사용 방법
CN118324910A (zh) Ccr8抗体的应用
RU2788092C2 (ru) Молекулы антител к pd-1 и их применения
HK40082317A (en) Fully human antibodies against ox40, method for preparing the same, and use thereof
HK40051088A (en) Use of il-15 protein complex joint pd-l1 antibody for treating tumor diseases
CN112439060A (zh) Pd-l1免疫疗法的新用途
HK40019885A (en) Antibody-cytokine engrafted proteins and methods of use in the treatment of cancer
HK1247122B (en) Combinations and uses thereof